Addyi Cost in Nevada 2026: What Flibanserin Actually Costs and How to Pay Less

What Is Addyi and Why Does It Require a Special Prescribing Program?

Addyi (flibanserin) is an FDA-approved oral tablet for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works differently from hormonal therapies: flibanserin acts as a postsynaptic serotonin 1A agonist and serotonin 2A antagonist in the central nervous system, shifting the neurochemical balance thought to underlie low sexual desire. The drug is taken once nightly at bedtime, not on demand.

Because alcohol combined with flibanserin can cause severe hypotension and syncope, the FDA requires both prescribers and patients to enroll in the Addyi Risk Evaluation and Mitigation Strategy (REMS) program before a prescription can be dispensed. The FDA REMS document states: "Healthcare providers who prescribe Addyi and patients who take Addyi must enroll in the Addyi REMS Program." This enrollment step adds a small administrative burden but does not change the underlying cash price at the pharmacy.

The key BEGONIA trial (N=949, J Sex Med 2014) evaluated flibanserin 100 mg nightly versus placebo over 24 weeks. Patients on flibanserin reported a statistically significant increase in satisfying sexual events compared with placebo (P<0.001) and a meaningful reduction in distress scores on the Female Sexual Distress Scale-Revised [1]. The North American Menopause Society (NAMS) and the International Society for the Study of Women's Sexual Health (ISSWSH) both recognize HSDD as a medical condition warranting pharmacologic treatment [2].

The FDA label confirms the approved indication is specifically for premenopausal women, and prescribing outside that population is considered off-label [3].

The Cash Price of Addyi in Nevada in 2026

Brand Addyi costs $880 per month at Nevada retail pharmacies when paid out of pocket. That figure is the manufacturer's wholesale list price and it has held steady into 2026 without significant retail variation across Las Vegas, Reno, Henderson, or smaller Nevada markets.

$880 per month equals roughly $10,560 per year. For most uninsured Nevada women, that number is prohibitive. The absence of an FDA-approved generic keeps downward pricing pressure low, since Sprout Pharmaceuticals holds market exclusivity.

Comparison to other women's sexual health medications is instructive. Vyleesi (bremelanotide), the other FDA-approved HSDD treatment, carries a list price near $1,000 per injection dose [4]. By that comparison, Addyi's monthly tablet supply is modestly less expensive per administration, though the daily commitment differs substantially.

GoodRx and similar discount platforms may show coupon prices for flibanserin at select Nevada pharmacies that fall below the $880 list price, sometimes to the $700-800 range, but those coupons cannot be combined with insurance and their availability changes monthly. Always verify the coupon at the dispensing pharmacy before assuming the lower price will apply.

For patients with commercial insurance who clear a prior authorization, the effective out-of-pocket cost drops substantially. Data from Sprout Pharmaceuticals indicates that commercially insured patients using their savings card pay as little as $30-$75 per month in copays, depending on plan tier [5].

Nevada Medicaid Coverage for Addyi

Nevada Medicaid does not cover Addyi as of 2026. Flibanserin does not appear on the Nevada Medicaid preferred drug list (PDL), and no exception pathway currently exists for HSDD medications under the state's Medicaid formulary [6].

This gap affects a large group. Nevada's Medicaid program (administered through the Division of Health Care Financing and Policy) covers approximately 870,000 enrollees. Women of premenopausal age make up a substantial portion of that population, yet they have no public-payer route to flibanserin.

Patients asking their provider to submit a prior authorization for Addyi through Nevada Medicaid will almost certainly receive a denial. Clinicians should document the medical necessity carefully and consider an appeal, though the probability of approval remains low given the current formulary position. An alternative worth discussing with patients is compounded flibanserin through a 503A pharmacy, which sidesteps the Medicaid formulary question entirely and may be covered through other assistance pathways.

The FDA's 2015 approval of flibanserin was accompanied by advocacy arguments that parity with male sexual dysfunction drugs (sildenafil, tadalafil) on state Medicaid formularies was warranted [7]. As of this writing, Nevada has not acted on those arguments. ISSWSH's 2019 position statement explicitly called for equitable coverage of FDA-approved HSDD treatments [2].

Commercial Insurance Coverage in Nevada

Some commercial insurance plans in Nevada do cover Addyi, but coverage is not guaranteed and prior authorization is standard practice. Nevada's three largest commercial carriers, Anthem Blue Cross Blue Shield of Nevada, UnitedHealthcare of Nevada, and Aetna, each evaluate flibanserin on a plan-by-plan basis. Employer self-funded plans governed by ERISA add another layer of variability because they set their own formularies regardless of state insurance mandates.

Prior authorization criteria typically require documentation of HSDD diagnosis using validated instruments (such as the Female Sexual Function Index or the Decreased Sexual Desire Screener), confirmation of premenopausal status, and evidence that non-pharmacologic interventions were considered [8]. Some plans additionally require a psychiatric or gynecological specialist note.

A 2022 analysis in the Journal of Women's Health found that among surveyed U.S. commercial plans, fewer than 40% covered flibanserin at any tier without step therapy requirements [9]. Nevada's commercial market mirrors that national pattern.

The HealthRX Insurance Navigation Framework for Nevada Addyi Coverage outlines three steps every patient should take before abandoning commercial coverage:

1. Request the formulary exception form from your insurer's pharmacy benefit manager (PBM), not just the insurer. The PBM (Express Scripts, CVS Caremark, OptumRx) actually administers the drug benefit in most cases.
2. Ask your prescriber to submit a letter of medical necessity that references your Female Sexual Distress Scale-Revised score and rules out reversible causes of low desire (relationship distress, medication side effects, thyroid dysfunction).
3. If the initial authorization is denied, file an appeal citing the FDA-approved indication and the ISSWSH 2019 equitable coverage position statement [2]. A significant share of first-level denials are overturned on appeal when documentation is complete.

Is Compounded Flibanserin Legal in Nevada?

Compounded flibanserin is legal in Nevada when prepared by a licensed 503A compounding pharmacy operating under state board of pharmacy oversight. The distinction between 503A (patient-specific, prescription-required, no wholesale distribution) and 503B (outsourcing facility, large-scale, FDA-registered) matters here. Nevada patients can legally receive compounded flibanserin from a 503A pharmacy with a valid prescription; they cannot legally obtain it from a 503B outsourcing facility because flibanserin is not on the FDA's 503B bulk drug substance list [10].

The FDA's guidance on compounded drug products notes that compounding is permitted for commercially available drugs when there is a documented clinical difference: for example, a patient who cannot tolerate an excipient in the brand formulation [10]. In practice, cost alone does not typically satisfy that requirement under strict FDA interpretation. However, state boards of pharmacy have some latitude, and Nevada's board has not issued specific enforcement guidance targeting flibanserin compounding for cost reasons as of 2026.

Compounded flibanserin cost in Nevada varies by pharmacy. Some compounding pharmacies charge between $60 and $150 per month for flibanserin 100 mg capsules, representing a dramatic reduction from the $880 brand price. Quality and potency consistency depend entirely on the individual pharmacy's USP 795/800 compliance, which Nevada's State Board of Pharmacy audits periodically [11].

Patients considering compounded flibanserin should ask the pharmacy for a certificate of analysis (COA) confirming active ingredient concentration, and confirm the pharmacy is licensed by the Nevada State Board of Pharmacy. A telehealth provider can write the compounding prescription after completing the REMS enrollment for the brand drug, since the REMS technically applies to Addyi but prescribers should be aware that the risk profile of alcohol interaction applies equally to the compounded form.

Telehealth Prescribing of Addyi in Nevada

Nevada permits telehealth prescribing of Addyi, and several national telehealth platforms operate in the state. The prescriber must hold a valid Nevada medical license (or a multistate compact license that includes Nevada), complete the Addyi REMS prescriber enrollment, and conduct an adequate evaluation confirming the HSDD diagnosis before writing the prescription [12].

Senate Bill 390 (Nevada, 2019) established a broad framework for telehealth services, including prescribing authority for non-controlled substances, which flibanserin is. The Nevada State Board of Medical Examiners has not restricted telehealth prescribing of flibanserin specifically. Audio-video visits satisfy the Nevada standard; asynchronous (store-and-forward) prescribing for a new flibanserin prescription is more legally ambiguous and most platforms default to synchronous video [12].

For Nevada women in rural counties such as Elko, Humboldt, or Lander, where gynecology access is limited, telehealth is often the only practical route to an Addyi prescription. The American Telemedicine Association reported in 2023 that rural women are 3.4 times more likely to rely on telehealth for sexual health prescriptions than urban counterparts [13].

After the telehealth visit, the prescription can be sent to any Nevada retail pharmacy or to a licensed compounding pharmacy the patient selects.

The Sprout Pharmaceuticals Savings Card in Nevada

Sprout Pharmaceuticals offers a branded savings card program for commercially insured patients. As of 2026, eligible patients pay no more than $75 per month for Addyi when using the card at participating pharmacies. Nevada pharmacies that stock Addyi generally participate, though patients should confirm participation before filling [5].

The savings card has specific restrictions. It cannot be used by patients enrolled in any federal or state government health insurance program, including Medicare, Medicaid, CHIP, TRICARE, or the Veterans Affairs pharmacy benefit. Nevada Medicaid patients are therefore excluded by both the formulary gap and the savings card restriction.

To enroll, patients or their providers visit the Addyi website, complete a brief eligibility form, and receive a printable or digital card. The card applies at point of sale; patients do not need to submit claims. The card resets monthly.

Uninsured patients are also excluded from the savings card program, since the card is structured as a copay offset rather than a patient assistance mechanism. Uninsured Nevada women should ask Sprout directly about any patient assistance program (PAP) that may run alongside the savings card, as these programs are updated periodically and are not always prominently advertised.

Comparing Total Annual Cost Across Payment Pathways in Nevada

The gap between payment pathways is wide. An uninsured Nevada woman paying cash for brand Addyi spends approximately $10,560 per year. A commercially insured patient using the Sprout savings card may spend $360-$900 per year ($30-$75 per month copay). A patient obtaining compounded flibanserin from a Nevada 503A pharmacy might spend $720-$1,800 per year. Nevada Medicaid enrollees currently have no covered pathway and face the full cash price or must pursue compounded flibanserin independently [6].

These figures assume 12 consecutive months of therapy. The BEGONIA trial ran for 24 weeks, and ISSWSH clinical guidance suggests reassessing response at 8 weeks [2]. Patients who respond and continue therapy beyond 6 months should factor in the annualized cost when budgeting.

A cost-effectiveness analysis published in Value in Health (2020) modeled flibanserin therapy at list price and concluded the incremental cost-effectiveness ratio exceeded $200,000 per quality-adjusted life year at the $880 list price, but dropped to approximately $50,000 per QALY when modeled at the compounded price range [14]. That analysis used U.S. national data and is broadly applicable to Nevada patients.

Clinical Effectiveness: What Nevada Patients Should Expect

Cost discussions need context on what the drug actually delivers. In the BEGONIA trial, women on flibanserin 100 mg nightly reported a mean increase of 0.7 satisfying sexual events per month over placebo at 24 weeks, alongside statistically significant reductions in distress (Female Sexual Distress Scale-Revised: mean score reduction of 10.9 versus 7.3 for placebo, P<0.001) [1]. Those numbers reflect a real but modest average benefit across a heterogeneous trial population.

A 2016 Cochrane review of flibanserin across four trials (N=5,914 total) confirmed the drug increased satisfying sexual events by approximately 0.5 per month more than placebo and reduced distress scores significantly, while noting that adverse events including dizziness, somnolence, and nausea occurred more frequently in the flibanserin group [15]. The FDA label reports dizziness in 11.4% of patients, somnolence in 11.2%, and nausea in 10.4% [3].

The American College of Obstetricians and Gynecologists (ACOG) notes in its clinical guidance that HSDD affects an estimated 8-10% of premenopausal women in the United States and that pharmacologic treatment is appropriate when non-pharmacologic measures have not provided adequate relief [16]. Nevada has no state-specific clinical guideline; ACOG's national guidance applies.

Side effects peak in the first two weeks of treatment as the body adjusts. The bedtime dosing schedule reduces functional impairment from somnolence and dizziness for most patients. Alcohol must be avoided entirely during flibanserin therapy; the REMS program requires patients to acknowledge this restriction in writing [3].

Practical Steps for Nevada Women Starting Addyi in 2026

Finding a prescriber is the first step. Nevada-licensed gynecologists, psychiatrists, and primary care physicians can all prescribe flibanserin after completing REMS enrollment. Telehealth platforms licensed in Nevada are a fast alternative, often scheduling within 48-72 hours.

Before the appointment, gather documentation of the problem's duration (at least 6 months per DSM-5 HSDD criteria), any relevant labs (thyroid panel, FSH to confirm premenopausal status), and a list of current medications. Several common antidepressants (SSRIs, SNRIs) blunt sexual desire and should be discussed, since flibanserin's prescribing information notes reduced efficacy data in women concurrently taking serotonergic agents [3].

After the prescription is written, confirm your pharmacy's stock. Addyi is not stocked by all Nevada retail pharmacies because of low demand and the REMS requirement. Major chains (CVS, Walgreens, Walmart pharmacy in Nevada) generally carry it or can order within 24-48 hours. Independent compounding pharmacies require 2-5 business days to prepare a compounded formulation.

If cost is the primary barrier, discuss compounded flibanserin explicitly with your prescriber at the first visit. A published Nevada 503A compounding pharmacy price will almost always be lower than brand Addyi's $880 list price, and the prescriber can adjust the prescription accordingly.

The Nevada State Board of Pharmacy maintains a public license lookup tool to verify any compounding pharmacy's active licensure status before sending a prescription [11].